Publications by authors named "Federica Tomatis"
Rationale & Objective: Rituximab is the first-choice therapy for patients with primary membranous nephropathy (MN) and nephrotic syndrome. However, approximately 30% of patients are treatment-resistant or become treatment-intolerant with hypersensitivity reactions upon repeated drug exposures. We aimed to assess whether ofatumumab, a fully human second-generation anti-CD20 antibody, could be a valuable alternative to rituximab in this population.
View Article and Find Full Text PDFArticle Synopsis
- - This study investigated the effects of eculizumab, a C5 inhibitor, on COVID-19 patients with respiratory issues, focusing on whether it could improve respiratory rates and overall disease outcomes.
- - Ten patients receiving eculizumab showed a significant decrease in respiratory rate over two weeks, while a control group of 65 did not experience similar improvements.
- - Eculizumab-treated patients had notably better outcomes regarding mortality and chronic complications compared to controls, indicating its potential benefits in treating severe COVID-19 cases.
Passive antibody therapy has been used to treat outbreaks of viral disease, including the ongoing pandemic of severe respiratory acute respiratory syndrome (SARS) coronavirus 2 (SARS-CoV-2) or COVID-19. However, the real benefits of the procedure are unclear. We infused a concentrated solution of neutralizing anti-SARS-CoV-2 antibodies obtained from a convalescent donor with a single session of double filtration plasmapheresis (DFPP) into a 56-year-old woman with long history of unremitting, severe COVID-19.
View Article and Find Full Text PDF